Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

quarterly sales

Sanofi reception

Sanofi narrows focus, shedding diabetes and cardiovascular research

New CEO Paul Hudson reveals strategy update

- PMLiVE

J&J splashes $750m on anti-inflammatory drug bermekimab

The drug is currently in phase 2 clinical development

- PMLiVE

J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

Both candidates are being studied in multiple myeloma

- PMLiVE

AstraZeneca’s Calquence impresses in previously untreated CLL

Takes the fight to AbbVie/J&J’s Imbruvica

- PMLiVE

J&J to FDA: there really is no asbestos in Baby Powder

Rejects findings that product contained 'sub-trace' levels of asbestos

- PMLiVE

AstraZeneca wins FDA approval for Calquence in chronic lymphoma

Takes the fight to AbbVie and J&J's lymphoma rival Imbruvica

- PMLiVE

J&J’s new Darzalex formulation OK’d for use in Europe

Extends use of multiple myeloma therapy even further

- PMLiVE

FDA advisors say no to empagliflozin in type 1 diabetes

Approval of Boehringer, Lilly-partnered drug expansion looks unlikely

- PMLiVE

J&J catches up to Merck, files Ebola vaccine in Europe

Company is also in discussion with the FDA in the US to support regulatory filings

- PMLiVE

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Hopes new product can offset continuing decline in franchise

- PMLiVE

UPDATED: Ohio opioid trial averted by last-minute settlement

Drug manufacturers reach settlement hours before trial set to begin

- PMLiVE

Janssen files Tremfya for psoriatic arthritis in Europe

Hopes to extend use beyond plaque psoriasis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links